Christian H. Ottensmeier
Distinguished in Melanoma

Christian H. Ottensmeier

University Of Southampton Tremona Road, 
Southampton, ENG, GB 
Distinguished in Melanoma
University Of Southampton Tremona Road, 
Southampton, ENG, GB 
OverviewLocationsClinical Research

Overview

Christian Ottensmeier practices in Southampton, United Kingdom. Mr. Ottensmeier is rated as a Distinguished expert by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Small Cell Lung Cancer (SCLC), Melanoma of the Eye, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 30 articles and participated in 3 clinical trials in the study of Melanoma.

Gender
Male

Locations

University Of Southampton Tremona Road, Southampton, ENG, United Kingdom
Other Locations
Tremona Road, Southampton, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial Tumours
A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial Tumours
Enrollment Status: Completed
Publish Date: December 16, 2025
Intervention Type: Biological
Study Phase: Phase 1
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drugs: AZD4547, Vistusertib, Palbociclib, Crizotinib, Selumetinib, Docetaxel, AZD5363, Osimertinib, Durvalumab, Sitravatinib, AZD6738
Study Phase: Phase 2
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma
Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Drug
Study Drug: BNT113
Study Phase: Phase 1/Phase 2
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Enrollment Status: Terminated
Publish Date: March 10, 2022
Intervention Type: Biological
Study Phase: Phase 2
Exercise regiMens Before and duRing Advanced Cancer thErapy: A Pilot Study to Investigate Improvements in Physical Fitness With Exercise Training Programme Before and During Chemotherapy in Advanced Lung Cancer Patients.
Exercise regiMens Before and duRing Advanced Cancer thErapy: A Pilot Study to Investigate Improvements in Physical Fitness With Exercise Training Programme Before and During Chemotherapy in Advanced Lung Cancer Patients.
Enrollment Status: Unknown
Publish Date: July 08, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Enrollment Status: Unknown
Publish Date: March 04, 2019
Intervention Type: Biological
Study Drug: PEG IFN Alfa-2b
Study Phase: Phase 3
A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Terminated
Publish Date: July 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

165 Total Publications

GPR25 promotes the formation of lung and liver tissue-resident memory CD8 T cells.
GPR25 promotes the formation of lung and liver tissue-resident memory CD8 T cells.
Journal: Science immunology
Published: November 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ottensmeier's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile